The DOI matches its Crossref record; 59 of the 60 references it cites were found in a registry or an index.
Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis
Open accessAbstract
CD8(+) T cells recognizing tumor-specific antigens are detected in cancer patients but are dysfunctional. Here we developed a tamoxifen-inducible liver cancer mouse model with a defined oncogenic driver antigen (SV40 large T-antigen) to follow the activation and differentiation of naive tumor-specific CD8(+) T (TST) cells after tumor initiation. Early during the pre-malignant phase of tumorigenesis, TST cells became dysfunctional, exhibiting phenotypic, functional, and transcriptional features similar to dysfunctional T cells isolated from late-stage human tumors. Thus, T cell dysfunction seen in advanced human cancers may already be established early during tumorigenesis. Although the TST cell dysfunctional state was initially therapeutically reversible, it ultimately evolved into a fixed state. Persistent antigen exposure rather than factors associated with the tumor microenvironment drove dysfunction. Moreover, the TST cell differentiation and dysfunction program exhibited features distinct from T cell exhaustion in chronic infections. Strategies to overcome this antigen-driven, cell-intrinsic dysfunction may be required to improve cancer immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Profiling adoptively transferred SV40 large T cell antigen (Tag+)–specific CD8+ T cells indicated that Tag+ T cells followed classic signs of exhaustion upon entry into the tumor-bearing livers (fig. S2D) (19).”
From Bile acid synthesis impedes tumor-specific T cell responses during liver cancer (2025) · cites this paper as [19]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Conversely, terminal Tex (Ttex) cells accumulate over time and respond poorly to ICB therapies8,11–13.”
From Proteotoxic stress response drives T cell exhaustion and immune evasion (2025) · cites this paper as [13]
Experimental — accuracy not yet measuredIn the citing paper
“Indeed, the T cell immune response to HCC antigens is reportedly dysfunctional and unreactive to HCC55.”
From Tumor-specific cholinergic CD4+ T lymphocytes guide immunosurveillance of hepatocellular carcinoma (2023) · cites this paper as [55]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 1×
“…studies have demonstrated that blocking inhibitory receptors (checkpoint blockade) can mediate functional rescue of unresponsive T cells in chronic infection or tumors (Barber et al., 2006; Brahmer et al., 2012; Perez-Gracia et al., 2014; (A) Tamoxifen (Tam)-inducible ASTxCre-ERT2 tumor model.”
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Tumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2005) · Nature · doi:10.1038/nature04444 · Cited by 4,057
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544
T cell receptor antagonist peptides induce positive selection.
Hogquist, K., Jameson, S., Heath, W., Howard, J. L., Bevan, M., & Carbone, F. (1994) · Cell · doi:10.1016/0092-8674(94)90169-4 · Cited by 3,252
Cited by
Sorted by citations
Items 401–500 of 726
Stromnes, I. M., Hulbert, A., Rollins, M. R., Basom, R., Delrow, J. J., Bonson, P., Burrack, A. L., Hingorani, S. R., & Greenberg, P. D. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003525 · Cited by 16
Self-citationHeterogeneity and Differentiation Trajectories of Infiltrating CD8+ T Cells in Lung Adenocarcinoma
Song, X., Zhao, G., Wang, G., & Gao, H. (2022) · Cancers · doi:10.3390/cancers14215183 · Cited by 15
Mistarz, A., Winkler, M., Battaglia, S., Liu, S., Hutson, A. D., Rokita, H., Gambotto, A. A., Odunsi, K. O., Singh, P. K., McGray, A. R., et al. (2023) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2023.02.002 · Cited by 15
Mitchell, E., Jindal, S., Chan, T., Narasimhan, J., Sivagnanam, S., Gray, E., Chang, Y. H., Weinmann, S. A., & Schedin, P. S. (2020) · Molecular Carcinogenesis · doi:10.1002/mc.23171 · Cited by 15
Loss of natural resistance to schistosome in T cell deficient rat
Lu, L., Hu, J., Chao, T., Chen, Z., Liu, Z., Luo, X., Liang, Y., He, P., & Zhang, L. (2020) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0008909 · Cited by 15
Costa, A. D. A., Chatterjee, J., Cobb, O. M., Cordell, E., Chao, A., Schaeffer, S., Goldstein, A. K., Dahiya, S. M., & Gutmann, D. H. (2021) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdab194 · Cited by 15
T-cell exhaustion in multiple myeloma
Żyłka, K., Kubicki, T., Gil, L., & Dytfeld, D. (2024) · Expert Review of Hematology · doi:10.1080/17474086.2024.2370552 · Cited by 15
New insights into T-cell exhaustion in liver cancer: from mechanism to therapy
Hao, L., Li, S., & Hu, X. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05083-5 · Cited by 15
Cell Identity and Spatial Distribution of PD‐1/PD‐L1 Blockade Responders
Li, X., Liu, Y., Gui, J., Gan, L., & Xue, J. (2024) · Advanced Science · doi:10.1002/advs.202400702 · Cited by 17
Wang, C., Lin, S.-C., Chang, K.-J., Cheong, H.-P., Wu, S.-R., Lee, C.-H., Chuang, M.-W., Chiou, S., Hsu, C., & Ko, P. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e39731 · Cited by 14
Vaccination against Nonmutated Neoantigens Induced in Recurrent and Future Tumors
Garrido, G., Schrand, B., Levay, A. K., Rabasa, A., Ferrantella, A. R., Silva, D. M. D., D’Eramo, F., Marijt, K. A., Zhang, Z., Kwon, D., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0020 · Cited by 14
Nero, C., Romito, I., Spadola, S., Romito, A., Turco, L. C., Cosentino, F., Ninno, M. D., Catena, U., Nardone, A. D. C., Moroni, R., et al. (2021) · Fertility and Sterility · doi:10.1016/j.fertnstert.2021.08.032 · Cited by 14
CRISPR Screens to Identify Regulators of Tumor Immunity
LaFleur, M. W., & Sharpe, A. H. (2021) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-070120-094725 · Cited by 16
Liao, J., Lai, H., Liu, C., Zhang, X., Ou, Q., Li, Q., Li, Y., Wang, Z., Liu, C., Wu, X., et al. (2023) · Cancer Science · doi:10.1111/cas.15804 · Cited by 14
Engineering Solutions for Mitigation of Chimeric Antigen Receptor T-Cell Dysfunction
Gavriil, A., Barisa, M., Halliwell, E., & Anderson, J. (2020) · Cancers · doi:10.3390/cancers12082326 · Cited by 13
Zhan, X., Hu, H., Liu, Y., Wan, H., Zheng, F., Chen, L., Liu, X., Xiong, J., Cui, X., Xu, S., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-013025 · Cited by 14
Overcoming key challenges in cancer immunotherapy with engineered T cells
Arcangeli, S., Mestermann, K., Weber, J., Bonini, C., Casucci, M., & Hudecek, M. (2020) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000664 · Cited by 13
Dynamic changes of exhaustion features in T cells during oral carcinogenesis
Xie, W., Shen, J., Wang, D., Guo, J., Li, Q., Wen, S., Dai, W., Wen, L., Lu, H., Fang, J., et al. (2022) · Cell Proliferation · doi:10.1111/cpr.13207 · Cited by 13
Tumor-Reactive CD8+ T Cells Enter a TCF1+PD-1− Dysfunctional State
Roetman, J. J., Erwin, M. M., Rudloff, M. W., Favret, N. R., Román, C. R. D., Apostolova, M. K. I., Murray, K. A., Lee, T., Lee, Y. A., & Philip, M. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0939 · Cited by 13
Self-citationKLF4: a multifunctional nexus connecting tumor progression and immune regulation
Ju, Y., Xiao, W., Mathis, B. J., & Shi, Y. Q. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1514780 · Cited by 13
Zhang, T., Yang, H., Sun, B., & Yao, F. (2021) · Aging · doi:10.18632/aging.202351 · Cited by 13
Loucif, H., Dagenais-Lussier, X., Beji, C., Telittchenko, R., Routy, J., & van Grevenynghe, J. (2020) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2020.02.004 · Cited by 12
Beyond CAR T cells: Engineered Vγ9Vδ2 T cells to fight solid tumors
Rafia, C., Harly, C., & Scotet, E. (2020) · Immunological Reviews · doi:10.1111/imr.12920 · Cited by 14
Mogat1 drives metabolic adaptations to evade immune surveillance
Wei, H., Niu, C., Shi, Y., Fang, Y., Yang, C., Li, J., & Xu, Z. (2025) · Nature Communications · doi:10.1038/s41467-025-62134-w · Cited by 12
The progress and perspective of nanomedicine in modulating the tumor immune microenvironment
Lin, N., Tan, K., Wei, Y., Xie, S., Liu, J., & Ma, X. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.10.002 · Cited by 13
Clinical Trials of Cellular Therapies in Solid Tumors
Secondino, S., Canino, C., Alaimo, D., Muzzana, M., Galli, G., Borgetto, S., Basso, S., Bagnarino, J., Pulvirenti, C., Comoli, P., et al. (2023) · Cancers · doi:10.3390/cancers15143667 · Cited by 12
B7-H4 reduces the infiltration of CD8+T cells and induces their anti-tumor dysfunction in gliomas
Qi, Y., Hu, L., Ji, C., Yang, X., Yao, J., Chen, D., & Yao, Y. (2024) · Neoplasia · doi:10.1016/j.neo.2024.101007 · Cited by 12
Shi, T., Shao, J., Ding, Y., Tang, H., Tan, X., Zhou, S., Yu, S., Wang, X., Yu, G., Feng, N., et al. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.06.011 · Cited by 13
Protective low-avidity anti-tumour CD8+ T cells are selectively attenuated by regulatory T cells
Sugiyarto, G., Prossor, D., Dadas, O., Arcia, D., Elliott, T. J., & James, E. (2020) · Immunotherapy Advances · doi:10.1093/immadv/ltaa001 · Cited by 12
Zhi, L., Su, X., Yin, M., Zhang, Z., Lü, H., Niu, Z., Guo, C., Zhu, W., & Zhang, X. (2021) · Cellular Immunology · doi:10.1016/j.cellimm.2021.104436 · Cited by 13
Solid Tumor Microenvironment Can Harbor and Support Functional Properties of Memory T Cells
Sullivan, P. M., Reed, S. J., Kalia, V., & Sarkar, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.706150 · Cited by 13
Eguren‐Santamaría, I., Melero, I., Rodríguez, I., Ortego, I., Armero, M., Gálvez‐Cancino, F., López‐Janeiro, Á., de Andrea, C. E., & Sanmamed, M. F. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-011279 · Cited by 13
Cieniewicz, B., Bhatta, A., Torabi, D., Baichoo, P., Saxton, M., Arballo, A., Nguyen, L., Thomas, S., Kethar, H., Kukutla, P., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.05.009 · Cited by 10
Cheng, H., & Zheng, Y. (2024) · PeerJ · doi:10.7717/peerj.16825 · Cited by 13
Li, Y., Cui, Q., Liu, S., Liu, L., Li, M. Y., Gao, J., Li, Z., Cui, W., Zhu, X., Kang, L., et al. (2024) · Cellular Oncology · doi:10.1007/s13402-024-00945-7 · Cited by 12
Epigenetics behind CD8+ T cell activation and exhaustion
Zu, H., & Chen, X. (2024) · Genes and Immunity · doi:10.1038/s41435-024-00307-1 · Cited by 13
Zhang, Z., Geng, C., Song, M., Liang, H., Zhou, K., Liu, Y., Wu, J., Huang, X., Zhou, J., Fan, J., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.01.027 · Cited by 13
T cells in the microenvironment of solid pediatric tumors: the case of neuroblastoma
Maggi, E., Landolina, N., Munari, E., Mariotti, F. R., Tumino, N., Vacca, P., Azzarone, B. G., & Moretta, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1544137 · Cited by 11
Zhou, M., Chen, M., Zheng, Z., Li, Q., Liao, L., Wang, Y., Xu, Y., Shu, G., Luo, J., Yang, T., et al. (2025) · Autophagy · doi:10.1080/15548627.2025.2503560 · Cited by 12
EGR1 as a potential marker of prognosis in extranodal NK/T-cell lymphoma
Lee, J. Y., Kim, J. H., Bang, H., Cho, J., Ko, Y. H., Kim, S. J., & Kim, W. S. (2021) · Scientific Reports · doi:10.1038/s41598-021-89754-8 · Cited by 11
STING signalling compensates for low tumour mutation burden to drive anti-tumour immunity
Tan, J., Egelston, C. A., Guo, W., Stark, J. M., & Lee, P. P. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105035 · Cited by 11
The prognostic value of tumor-associated macrophages in glioma patients
Shen, Y., Zheng, D., Hu, D., Ma, B., Cai, C., Chen, W., Zeng, J., Luo, J., Xiao, D., Zhao, Y., et al. (2023) · Medicine · doi:10.1097/md.0000000000035298 · Cited by 12
Lint, S. V., Parys, A. V., Eeckhout, B. V. D., Vandamme, N., Plaisance, S., Verhee, A., Catteeuw, D., Rogge, E., Geest, J. D., Vanderroost, N., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01908-6 · Cited by 10
Chang, C. (2024) · American Journal of Cancer Research · doi:10.62347/aryh6451 · Cited by 10
van der Sluis, R. M., García‐Rodríguez, J. L., Nielsen, I. H., Gris‐Oliver, A., Becker, J., Costa, B., Chaudhry, M. Z., Werner, M., Laustsen, A., Pedersen, J. G., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115413 · Cited by 10
A primer on recent developments in cancer immunotherapy, with a focus on neoantigen vaccines
Tokuyasu, T. A., & Huang, J. (2018) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2017.52 · Cited by 10
Nader, J. S., Abadie, J., Deshayes, S., Boissard, A., Blandin, S., Blanquart, C., Boisgerault, N., Coqueret, O., Guette, C., Grégoire, M., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24632 · Cited by 10
Yan, H., Huang, J., Li, Y., & Zhao, B. (2024) · Biology of Sex Differences · doi:10.1186/s13293-024-00598-z · Cited by 11
Lundh, S. M., Jung, I.-Y., Dimitri, A. J., Vora, A., Melenhorst, J. J., Jadlowsky, J. K., & Fraietta, J. A. (2020) · Clinical and Experimental Medicine · doi:10.1007/s10238-020-00628-1 · Cited by 10
Kane, R. A., Christodoulides, N., Jensen, I. M., Becker, D. J., Mansfield, K. L., & Savage, A. E. (2021) · Gene · doi:10.1016/j.gene.2021.145800 · Cited by 10
Low-Dose JAK3 Inhibition Improves Antitumor T-Cell Immunity and Immunotherapy Efficacy
Dammeijer, F. F., van Gulijk, M., Klaase, L., van Nimwegen, M., Bouzid, R., Hoogenboom, R., Joosse, M. E., Hendriks, R. W., van Hall, T., & Aerts, J. G. J. V. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0943 · Cited by 10
Mechanism of resistance to immune checkpoint inhibitors
Pandey, M. R., & Ernstoff, M. S. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2018.015 · Cited by 9
Koh, J., Lee, D., Kim, S., Song, S. G., Han, B., Jeong, H., Kim, Y. A., Keam, B., Lee, S., Kim, K., et al. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-24-0071 · Cited by 9
Hu, L., Wang, Z., Liao, Y., Jiang, X., Lian, H., & Lin, Z. (2024) · Oncology and Translational Medicine · doi:10.1097/ot9.0000000000000041 · Cited by 9
Füchsl, F., Untch, J., Kavaka, V., Zuleger, G., Braun, S., Schwanzer, A., Jarosch, S., Vogelsang, C., Krätzig, N. D. A., Gosmann, D., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53911-0 · Cited by 11
Membrane-derived biomimetic nanovesicles in anti-tumor immunotherapy: Advances and outlook
Zhang, X., Jing, H., Wang, Y., Mu, S., Wang, X., Zheng, H., Chen, Y., Wang, K., Sun, J., Bi, J., et al. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.01.019 · Cited by 11
TOX drives CD4+ TH1 effector function, antitumor immunity and autoimmune pathology
Naizir, B., Scott, A., Zumbo, P., Grassmann, S. A., Frost, J. N., Sun, J. C.-Y., Betel, D., & Schietinger, A. (2026) · Nature Immunology · doi:10.1038/s41590-026-02453-2 · Cited by 11
Self-citationRegulation and Immunotherapeutic Targeting of the Epigenome in Exhausted CD8 T Cell Responses
Ford, B. R., & Poholek, A. C. (2023) · The Journal of Immunology · doi:10.4049/jimmunol.2200681 · Cited by 9
Shen, H.-Y., Xu, J.-L., Zhu, Z., Xu, H.-P., Liang, M., Xu, D., Chen, W., Tang, J., Zheng, F., & Zhang, J. (2023) · Neoplasia · doi:10.1016/j.neo.2023.100942 · Cited by 9
Pollard, J. M., Hynes, G. E., Yin, D., Mandal, M., Gounari, F., Alegre, M., & Chong, A. S. (2024) · JCI Insight · doi:10.1172/jci.insight.176381 · Cited by 9
Metabolites, genome organization, and cellular differentiation gene programs
Chisolm, D. A., & Weinmann, A. S. (2018) · Current Opinion in Immunology · doi:10.1016/j.coi.2018.01.005 · Cited by 9
Nair, V. S., Saleh, R., Taha, R. Z., Toor, S. M., Murshed, K., Ahmed, A., Kurer, M. A., Nada, M. A., Al‐Ejeh, F., & Elkord, E. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1825178 · Cited by 9
SLC17A2 Expression Correlates with Prognosis and Immune Infiltrates in Hepatocellular Carcinoma
Jiang, Z., Chen, X., & Jiang, Z. (2022) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207325666220126104358 · Cited by 9
Füchsl, F., & Krackhardt, A. M. (2022) · Cancers · doi:10.3390/cancers14174192 · Cited by 9
Cosma, G. L., & Eisenlohr, L. C. (2018) · F1000Research · doi:10.12688/f1000research.14115.1 · Cited by 9
Cross, E. W., Blain, T. J., Mathew, D., & Kedl, R. M. (2019) · PLoS ONE · doi:10.1371/journal.pone.0211446 · Cited by 9
Yu, H., Nishio, H., Barbi, J. J., Mitchell-Flack, M., Vignali, P., Zheng, Y., Lebid, A., Chang, K., Fu, J. L., Higgins, M., et al. (2024) · eLife · doi:10.7554/elife.96812 · Cited by 9
Longhini, A. L. F., Fernández-Maestre, I., Kennedy, M. C., Wereski, M. G., Mowla, S., Xiao, W., Lowe, S. W., Levine, R. L., & Gardner, R. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1374943 · Cited by 8
Zou, S., Zhang, L., Jiang, C., Li, F., Yang, Y., Deng, X., Zhang, J., Chen, H., Jiang, L., Cheng, X., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217134 · Cited by 9
Wu, B., Koehler, A. N., & Westcott, P. M. K. (2024) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2024.08.002 · Cited by 9
Hu, H., Ning, S., Liu, F., Zhang, Z., Zeng, W., Liu, Y., Liao, Z., Zhang, H., & Zhang, Z. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c21998 · Cited by 8
GFI1-driven transcriptional and epigenetic programs maintain CD8+ T cell stemness and persistence
Chaudhry, M. Z., Chen, E., Man, H. O., Jones, A., Denman, R., Yu, H., Huang, Q., Ilich, A., Schreuder, J., Navarro, S., et al. (2025) · Nature Immunology · doi:10.1038/s41590-025-02151-5 · Cited by 8
Du, B., Wang, J., Zheng, J., Huo, J., & Wang, P. (2023) · Scientific Reports · doi:10.1038/s41598-023-43732-4 · Cited by 8
Markers of Immune Cell Exhaustion as Predictor of Survival in Surgically-Treated Early-Stage NSCLC
Sellmer, L., Kovács, J., Walter, J., Kumbrink, J., Neumann, J. H. L., Kauffmann-Guerrero, D. E., Kiefl, R., Schneider, C., Jung, A., Behr, J., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.858212 · Cited by 8
Bernhardt, S. M., Mitchell, E., Stamnes, S., Hoffmann, R. J., Calhoun, A., Klug, A., Russell, T. D., Pennock, N. D., Walker, J. M., & Schedin, P. S. (2023) · Cancers · doi:10.3390/cancers15082257 · Cited by 8
Conceptual Development of Immunotherapeutic Approaches to Gastrointestinal Cancer
Aderonke, A. B., Ibrahim, R. B., & Huang, Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184624 · Cited by 8
ZFP36 disruption is insufficient to enhance the function of mesothelin-targeting human CAR-T cells
Mai, D., Boyce, T., Mehta, A., Reff, J., Scholler, J., Sheppard, N. C., & June, C. H. (2024) · Scientific Reports · doi:10.1038/s41598-024-53769-8 · Cited by 7
Gfi1 controls the formation of effector-like CD8+ T cells during chronic infection and cancer
Ojo, O. A., Shen, H., Ingram, J. T., Bonner, J. A., Welner, R. S., Lacaud, G., Zajac, A. J., & Shi, L. Z. (2025) · Nature Communications · doi:10.1038/s41467-025-59784-1 · Cited by 9
Targeting the roots of myeloid malignancies with T cell receptors
Földvári, Z., Brennan, M. S., Titov, A., Jacobsen, S. E. W., & Olweus, J. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00857-0 · Cited by 8
Gan, Z., Huang, J., Duan, S., Lin, M., Deng, S., Huang, S., Wang, J., Shuai, X., & Xiao, Z. (2025) · Nature Communications · doi:10.1038/s41467-025-67254-x · Cited by 8
KLRG1-expressing CD8+ T cells are exhausted and polyfunctional in patients with chronic hepatitis B
Wang, L., Liao, F., Yang, L., Jiang, L., Duan, L., Wang, B., Mu, D., Chen, J., Huang, Y., Hu, Q., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0303945 · Cited by 7
Multimodal delineation of a layer of effector function among exhausted CD8 T cells in tumors
Ray, A., Bassette, M. A., Hu, K. H., Pass, L. F., Courau, T., Samad, B., Combes, A. J., Johri, V., Davidson, B. R., Wai, K. C., et al. (2025) · Science Immunology · doi:10.1126/sciimmunol.adt3537 · Cited by 10
Dietary fat and male sex increase histopathological changes in a mouse model of oral cancer
Green, J. M., Ciancio, M. J., Góral, J., Pytynia, M., Pitstick, L. D., Meyer, A., Nguyen, A., Lee, K., Barakat, A., & Jham, B. C. (2020) · Oral Diseases · doi:10.1111/odi.13542 · Cited by 7
Emerging Strategies of Engineering and Tracking Dendritic Cells for Cancer Immunotherapy
Gao, Y., Wang, Z., Cui, Y., Xu, M., & Weng, L. (2022) · ACS Applied Bio Materials · doi:10.1021/acsabm.2c00790 · Cited by 6
Spear, S., McNeish, I. A., & Capasso, M. (2019) · Journal of Visualized Experiments · doi:10.3791/60622 · Cited by 7
Divergent fates of antigen-specific CD8+ T cell clones in mice with acute leukemia
Chen, X., MacNabb, B. W., Flood, B. A., Blazar, B. R., & Kline, J. P. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109991 · Cited by 7
Jiménez, I., Tazón‐Vega, B., Abrisqueta, P., Nieto, J. C., Bobillo, S., Palacio, C., Carabia, J., Valdés‐Mas, R., Munuera, M., Puigdefàbregas, L., et al. (2021) · Biomarker Research · doi:10.1186/s40364-021-00290-z · Cited by 8
Gene expression signatures identify biologically and clinically distinct tuberculosis endotypesPreprint
DiNardo, A. R., Gandhi, T., Heyckendorf, J., Grimm, S. L., Rajapakshe, K., Nishiguchi, T., Reimann, M., Kahari, J., Dlamini, Q., Lange, C. G., et al. (2020) · medRxiv · doi:10.1101/2020.05.13.20100776 · Cited by 7
Elliot, T. A. E., Lecky, D. A. J., & Bending, D. (2023) · Essays in Biochemistry · doi:10.1042/ebc20220247 · Cited by 6
In vivo detection of immune responses via cytokine activity labeling
Lu, G., Zhang, S., Feng, M., Kim, E., Cho, D., Kim, J. H., Caris, H., Silberstein, L., Choi, G. B., & Huh, J. R. (2026) · Cell · doi:10.1016/j.cell.2025.12.011 · Cited by 6
Phenotypic and Immunometabolic Aspects on Stem Cell Memory and Resident Memory CD8+ T Cells
Manna, M. P. L., Azgomi, M. S., Tamburini, B., Badami, G. D., Mohammadnezhad, L., Dieli, F., & Caccamo, N. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.884148 · Cited by 6
Peng, K., Xie, J., Xu, T., Chen, M., Guo, Y., Wang, Y., Qiu, H., Wu, D., Zeng, Z., Chen, S., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1302356 · Cited by 6
Epigenetic regulation of the tumor microenvironment: A leading force driving pancreatic cancer
Vera, R. E., Lamberti, M. J., González, A. L., & Fernández-Zapico, M. E. (2024) · Pancreatology · doi:10.1016/j.pan.2024.07.005 · Cited by 6
TMED inhibition suppresses cell surface PD-1 expression and overcomes T cell dysfunction
Vredevoogd, D. W., Apriamashvili, G., Levy, P. L., Sinha, S., Huinen, Z. R., Visser, N. L., de Bruijn, B., Boshuizen, J., Veen, S. E. V. H.-V., Ligtenberg, M. A., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010145 · Cited by 6
Qiu, X., Tarantino, P., Li, R., Grinshpun, A., Gupta, H. V., Hughes, M. E., Kirkner, G. J., Scholl, L., Johnson, B. E., Meyerson, M. M., et al. (2025) · ESMO Open · doi:10.1016/j.esmoop.2024.104111 · Cited by 6
Bennion, K. B., Bazzano, J. M. R., Liu, D., Wagener, M. E., Paulos, C. M., & Ford, M. L. (2025) · JCI Insight · doi:10.1172/jci.insight.182563 · Cited by 6
Oncolytic Vaccinia Virus Armed with GM-CSF and IL-7 Enhances Antitumor Immunity in Pancreatic Cancer
Yan, W., Xuan, Y., Wang, R., Huan, Z., Guo, Y., Dun, H., Xu, L., Han, R., Sun, X., Si, L., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13040882 · Cited by 6
T Cell Receptors for Gene Transfer in Adoptive T Cell Therapy
Sharma, P. A., & Kranz, D. M. (2019) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.2019030788 · Cited by 6
Duhen, T. M., Gough, M. J., Leidner, R. S., & Stanton, S. E. (2022) · Frontiers in Oral Health · doi:10.3389/froh.2022.902160 · Cited by 6
Song, J., Huang, F., Chen, L., Feng, K., Jian, F., Huang, T., & Cai, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.976262 · Cited by 6
Metadata
- Authors
- Schietinger, A., Philip, M., Krisnawan, V. E., Chiu, E. Y., Delrow, J. J., Basom, R. S., Lauer, P., Brockstedt, D. G., Knoblaugh, S. E., Hämmerling, G. J., Schell, T. D., Garbi, N., & Greenberg, P. D.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- University of Washington (US)
- Fred Hutch Cancer Center (US)
- Aduro BioTech (United States) (US)
- German Cancer Research Center (DE)
- Pennsylvania State University (US)
- University of Bonn (DE)
- Corresponding author
- Schietinger, Andrea
- Greenberg, Philip D.
- ORCID
- Venue
- Immunity
- Publisher
- Elsevier BV
- Published
- 2016-08
- Volume
- 45
- Issue
- 2
- Pages
- 389-401
- ISSN
- 1074-7613 (ISSN-L)
- PMC
- PMC5119632
- OpenAlex
- W2514996992
- Cited by
- 720
- References
- 60
- Citations by year
- 2026: 45 · 2025: 77 · 2024: 93 · 2023: 84 · 2022: 78 · 2021: 103 · 2020: 99 · 2019: 61 · 2018: 50 · 2017: 25 · 2016: 5
- FWCI
- 25.49
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Immunity (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R00CA172371, K99CA172371, K08CA158069, R01CA033084, P30CA008748, P30CA015704)
- National Institute of Allergy and Infectious Diseases (R21AI107776)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- tumor-specific T cells, CD8+ T cell dysfunction, carcinogenesis, SV40 large T antigen, liver cancer, T cell differentiation, T cell exhaustion, cancer immunotherapy
- MeSH terms
- Animals, Antigens, Polyomavirus Transforming, Cell Differentiation, Cells, Cultured, Disease Models, Animal, Humans, Liver Neoplasms, Lymphocyte Activation, Mice, Inbred C57BL, Mice, Transgenic, Tamoxifen, Immunotherapy, Adoptive, Cellular Senescence, CD8-Positive T-Lymphocytes, Cancer Vaccines, Mice, Tumor Microenvironment, Carcinogenesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
